Dye Sensitizers for Photodynamic Therapy
Top Cited Papers
Open Access
- 6 March 2013
- Vol. 6 (3), 817-840
- https://doi.org/10.3390/ma6030817
Abstract
Photofrin® was first approved in the 1990s as a sensitizer for use in treating cancer via photodynamic therapy (PDT). Since then a wide variety of dye sensitizers have been developed and a few have been approved for PDT treatment of skin and organ cancers and skin diseases such as acne vulgaris. Porphyrinoid derivatives and precursors have been the most successful in producing requisite singlet oxygen, with Photofrin® still remaining the most efficient sensitizer (quantum yield = 0.89) and having broad food and drug administration (FDA) approval for treatment of multiple cancer types. Other porphyrinoid compounds that have received approval from US FDA and regulatory authorities in other countries include benzoporphyrin derivative monoacid ring A (BPD-MA), meta-tetra(hydroxyphenyl)chlorin (m-THPC), N-aspartyl chlorin e6 (NPe6), and precursors to endogenous protoporphyrin IX (PpIX): 1,5-aminolevulinic acid (ALA), methyl aminolevulinate (MAL), hexaminolevulinate (HAL). Although no non-porphyrin sensitizer has been approved for PDT applications, a small number of anthraquinone, phenothiazine, xanthene, cyanine, and curcuminoid sensitizers are under consideration and some are being evaluated in clinical trials. This review focuses on the nature of PDT, dye sensitizers that have been approved for use in PDT, and compounds that have entered or completed clinical trials as PDT sensitizers.Keywords
This publication has 74 references indexed in Scilit:
- Optimal Photosensitizers for Photodynamic Therapy of Infections Should Kill Bacteria but Spare NeutrophilsPhotochemistry and Photobiology, 2011
- Preclinical Study of the Novel Vascular Occluding Agent, WST11, for Photodynamic Therapy of the Canine ProstateJournal of Urology, 2011
- Preliminary Clinical and Pharmacologic Investigation of Photodynamic Therapy with the Silicon Phthalocyanine Photosensitizer Pc 4 for Primary or Metastatic Cutaneous CancersFrontiers in Oncology, 2011
- Past, Present, and Future of Molecular and Cellular OncologyFrontiers in Oncology, 2011
- Photodynamic Therapy and the Development of Metal-Based PhotosensitisersMetal-Based Drugs, 2008
- Motexafin Lutetium-Photodynamic Therapy of Prostate Cancer: Short- and Long-Term Effects on Prostate-Specific AntigenClinical Cancer Research, 2008
- Potentiation of the Antitumor Effect of Merocyanine 540‐mediated Photodynamic Therapy by Amifostine and Amphotericin BPhotochemistry and Photobiology, 2006
- Narrowband UVB phototherapy in skin conditions beyond psoriasisJournal of the American Academy of Dermatology, 2005
- Photodynamic Therapy (PDT)Resonance, 2000
- Tumour photosensitizers: approaches to enhance the selectivity and efficiency of photodynamic therapyJournal of Photochemistry and Photobiology B: Biology, 1996